Stay updated on Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page
- Check3 days agoChange DetectedThe study record now includes a Locations section with multiple site locations (Arizona, California, Colorado, Florida, Maryland, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas, Washington, Alberta, Ontario, Chiba, Tokyo, Lanarkshire). The previous location listings were removed, and the revision is v3.3.3.SummaryDifference1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed. This update pertains to versioning and does not modify any study data, eligibility criteria, or listed locations.SummaryDifference0.0%

- Check39 days agoChange DetectedA government funding status notice banner was removed from the page, eliminating the warning about updates and operating status. The study details and main content remain unchanged.SummaryDifference0.2%

- Check53 days agoChange DetectedResults for the study are now posted, including primary/secondary outcomes and updated completion dates.SummaryDifference0.3%

- Check82 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference2%

- Check89 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.